Drugs / V932
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00647114 | Aug 2007 → Sep 2008 | cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V932 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00647114 ↗ |
| Modality | Vaccine | “V932, a dicistronic adenovirus subtype-6 viral vector vaccine coding for the same antigens” PMID 23497415 ↗ Mar 2013 |